Maravai LifeSciences (MRVI) Competitors $2.40 -0.05 (-1.84%) Closing price 03:59 PM EasternExtended Trading$2.40 0.00 (-0.21%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock MRVI vs. IMVT, GMTX, RXRX, CPRX, KNSA, OGN, ALVO, CNTA, IBRX, and TARSShould you be buying Maravai LifeSciences stock or one of its competitors? The main competitors of Maravai LifeSciences include Immunovant (IMVT), Gemini Therapeutics (GMTX), Recursion Pharmaceuticals (RXRX), Catalyst Pharmaceuticals (CPRX), Kiniksa Pharmaceuticals International (KNSA), Organon & Co. (OGN), Alvotech (ALVO), Centessa Pharmaceuticals (CNTA), ImmunityBio (IBRX), and Tarsus Pharmaceuticals (TARS). These companies are all part of the "pharmaceutical products" industry. Maravai LifeSciences vs. Its Competitors Immunovant Gemini Therapeutics Recursion Pharmaceuticals Catalyst Pharmaceuticals Kiniksa Pharmaceuticals International Organon & Co. Alvotech Centessa Pharmaceuticals ImmunityBio Tarsus Pharmaceuticals Immunovant (NASDAQ:IMVT) and Maravai LifeSciences (NASDAQ:MRVI) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, profitability, earnings, institutional ownership and dividends. Which has more risk and volatility, IMVT or MRVI? Immunovant has a beta of 0.66, meaning that its share price is 34% less volatile than the S&P 500. Comparatively, Maravai LifeSciences has a beta of 0.28, meaning that its share price is 72% less volatile than the S&P 500. Is IMVT or MRVI more profitable? Immunovant has a net margin of 0.00% compared to Maravai LifeSciences' net margin of -90.03%. Maravai LifeSciences' return on equity of -17.60% beat Immunovant's return on equity.Company Net Margins Return on Equity Return on Assets ImmunovantN/A -80.99% -72.23% Maravai LifeSciences -90.03%-17.60%-9.30% Which has preferable valuation and earnings, IMVT or MRVI? Maravai LifeSciences has higher revenue and earnings than Immunovant. Immunovant is trading at a lower price-to-earnings ratio than Maravai LifeSciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioImmunovantN/AN/A-$413.84M-$2.85-5.25Maravai LifeSciences$259.18M2.35-$144.85M-$1.36-1.75 Do analysts recommend IMVT or MRVI? Immunovant currently has a consensus price target of $35.20, suggesting a potential upside of 135.45%. Maravai LifeSciences has a consensus price target of $5.75, suggesting a potential upside of 141.09%. Given Maravai LifeSciences' higher possible upside, analysts clearly believe Maravai LifeSciences is more favorable than Immunovant.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Immunovant 0 Sell rating(s) 3 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.83Maravai LifeSciences 1 Sell rating(s) 7 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.25 Do institutionals & insiders hold more shares of IMVT or MRVI? 47.1% of Immunovant shares are owned by institutional investors. Comparatively, 50.3% of Maravai LifeSciences shares are owned by institutional investors. 1.8% of Immunovant shares are owned by insiders. Comparatively, 2.1% of Maravai LifeSciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Does the media favor IMVT or MRVI? In the previous week, Immunovant and Immunovant both had 4 articles in the media. Immunovant's average media sentiment score of 1.65 beat Maravai LifeSciences' score of 1.25 indicating that Immunovant is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunovant 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Maravai LifeSciences 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryMaravai LifeSciences beats Immunovant on 9 of the 15 factors compared between the two stocks. Get Maravai LifeSciences News Delivered to You Automatically Sign up to receive the latest news and ratings for MRVI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MRVI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MRVI vs. The Competition Export to ExcelMetricMaravai LifeSciencesMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$609.03M$10.81B$5.76B$9.75BDividend YieldN/A1.84%4.40%4.10%P/E Ratio-1.7522.2630.8325.91Price / Sales2.3530.06469.77121.46Price / Cash3.9625.8925.7828.79Price / Book1.053.589.466.03Net Income-$144.85M$211.94M$3.27B$265.29M7 Day Performance-7.20%3.73%2.37%2.86%1 Month Performance-11.34%9.73%3.88%1.23%1 Year Performance-73.23%-9.16%30.52%19.11% Maravai LifeSciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MRVIMaravai LifeSciences4.0087 of 5 stars$2.41-1.8%$5.75+139.1%-72.5%$614.14M$259.18M-1.77610Gap UpIMVTImmunovant2.927 of 5 stars$15.26+0.3%$35.20+130.7%-53.0%$2.65BN/A0.00120GMTXGemini TherapeuticsN/A$59.86-1.4%N/A+22.1%$2.59BN/A-59.8630RXRXRecursion Pharmaceuticals2.3464 of 5 stars$5.52-4.3%$7.00+26.8%-36.7%$2.51B$58.84M0.00400CPRXCatalyst Pharmaceuticals4.8976 of 5 stars$20.23flat$33.20+64.1%+3.7%$2.48B$491.73M12.2680News CoveragePositive NewsGap UpKNSAKiniksa Pharmaceuticals International2.6092 of 5 stars$33.72+1.0%$41.17+22.1%+23.3%$2.47B$423.24M843.21220OGNOrganon & Co.4.6477 of 5 stars$9.27-1.8%$18.00+94.2%-57.9%$2.45B$6.40B2.674,000Positive NewsALVOAlvotech2.7424 of 5 stars$9.00+12.2%$14.00+55.6%-28.9%$2.42B$491.98M18.241,032Gap UpHigh Trading VolumeCNTACentessa Pharmaceuticals2.3548 of 5 stars$17.59-2.5%$28.10+59.7%+32.4%$2.42B$6.85M0.00200IBRXImmunityBio2.5181 of 5 stars$2.43-4.7%$10.75+342.4%-45.6%$2.41B$14.74M0.00590TARSTarsus Pharmaceuticals1.8764 of 5 stars$54.61+0.7%$66.67+22.1%+124.2%$2.29B$182.95M0.0050News CoveragePositive News Related Companies and Tools Related Companies IMVT Alternatives GMTX Alternatives RXRX Alternatives CPRX Alternatives KNSA Alternatives OGN Alternatives ALVO Alternatives CNTA Alternatives IBRX Alternatives TARS Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MRVI) was last updated on 8/25/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Maravai LifeSciences Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Maravai LifeSciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access